BeiGene, Ltd. (NASDAQ:BGNE) COO Xiaobin Wu Sells 5,556 Shares

BeiGene, Ltd. (NASDAQ:BGNE) COO Xiaobin Wu sold 5,556 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $189.65, for a total transaction of $1,053,695.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Xiaobin Wu also recently made the following trade(s):

• On Monday, June 24th, Xiaobin Wu sold 1,459 shares of BeiGene stock. The stock was sold at an average price of $159.79, for a total value of $233,133.61.

BeiGene Stock Up 1.6 %

BGNE stock opened at $191.58 on Friday. BeiGene, Ltd. has a fifty-two week low of $126.97 and a fifty-two week high of $213.83. The company has a market capitalization of $18.56 billion, a price-to-earnings ratio of -25.31 and a beta of 0.59. The business’s 50 day moving average price is $169.96 and its two-hundred day moving average price is $161.41. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.75 and a current ratio of 1.98.

BeiGene (NASDAQ:BGNE) last issued its earnings results on Wednesday, August 7th. The company reported ($1.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.27) by $1.12. BeiGene had a negative net margin of 16.91% and a negative return on equity of 14.93%. The business had revenue of $929.20 million during the quarter, compared to analysts’ expectations of $810.34 million. During the same period in the previous year, the company earned ($3.64) earnings per share. The business’s revenue for the quarter was up 56.1% compared to the same quarter last year. As a group, analysts forecast that BeiGene, Ltd. will post -5.13 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently issued reports on BGNE shares. TD Cowen raised their price target on BeiGene from $236.00 to $254.00 and gave the stock a “buy” rating in a research report on Thursday, May 9th. Citigroup raised their target price on shares of BeiGene from $269.00 to $288.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Bank of America decreased their target price on shares of BeiGene from $180.00 to $152.50 and set a “neutral” rating on the stock in a research note on Tuesday, July 9th. Finally, JPMorgan Chase & Co. increased their price target on shares of BeiGene from $194.00 to $200.00 and gave the company an “overweight” rating in a research report on Tuesday, August 20th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, BeiGene currently has a consensus rating of “Moderate Buy” and an average target price of $239.81.

Hedge Funds Weigh In On BeiGene

Hedge funds have recently added to or reduced their stakes in the company. Capital International Investors increased its holdings in shares of BeiGene by 11.5% in the 1st quarter. Capital International Investors now owns 7,064,428 shares of the company’s stock worth $1,104,806,000 after purchasing an additional 727,556 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of BeiGene by 6.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,026,094 shares of the company’s stock valued at $316,862,000 after buying an additional 117,905 shares during the last quarter. Capital International Inc. CA increased its holdings in BeiGene by 6.0% in the 1st quarter. Capital International Inc. CA now owns 858,364 shares of the company’s stock worth $134,240,000 after buying an additional 48,615 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in BeiGene in the 2nd quarter worth about $54,412,000. Finally, First Trust Advisors LP bought a new position in BeiGene during the 4th quarter valued at about $39,632,000. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.